17α-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis

Obstetrics and Gynecology

Volumn 108, Issue 3, 2006, Pages 492-499

  Odibo, Anthony O ^a   Stamilio, David M ^b   Macones, George A ^b   Polsky, Daniel ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; PROGESTERONE DERIVATIVE;

ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; FEMALE; GESTATIONAL AGE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LABOR COMPLICATION; MULTIVARIATE ANALYSIS; PARITY; PREGNANCY; PREMATURE LABOR; PREMATURITY; RECURRENT DISEASE; RISK FACTOR; UNITED STATES; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HOSPITAL ADMISSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SENSITIVITY ANALYSIS;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; GESTATIONAL AGE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; HYDROXYPROGESTERONES; MULTIVARIATE ANALYSIS; OBSTETRIC LABOR COMPLICATIONS; OBSTETRIC LABOR, PREMATURE; PARITY; PREGNANCY; PREMATURE BIRTH; PROGESTINS; RECURRENCE; RISK FACTORS; UNITED STATES;

EID: 33748375575     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000232503.92206.d8     Document Type: Article

References (25)

1. Hamilton BE, Martin JA, Ventura SJ, Sutton PD, Menacker F. Births: preliminary data for 2004. Natl Vital Stat Rep 2005;54:1-17.
2. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990;97:149-54.
3. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17α-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85.
4. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419-24.
5. American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol 2003;102:1115-6.
6. Hauth JC, Gilstrap LC, Brekken AL, Hauth JM. The effect of 17 [alpha]-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 1983;146:187-90.
7. Johnson JW, Austin KL, Jones GS, Davis G, King TM. Efficacy of 17 [alpha]-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975;293:675-80.
8. Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, et al. Prevention of premature labor by 17 [alpha]-hydroxyprogesterone caproate. Am J Obstet Gynecol 1985;151:574-7.
9. Hartikainen-Sorri AL, Kauppila A, Tuimala R. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980;56:692-5.
10. LeVine L. Habitual abortion: a controlled clinical study of progestational therapy. West J Surg Obstet Gynecol 1964;72:30-6.
11. Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 2005;105:273-9.
12. Simpson KN, Lynch SR. Cost savings from the use of antenatal steroids to prevent respiratory distress syndrome and related conditions in premature infants. Am J Obstet Gynecol 1995;173:316-21.
13. Mercer BM, Goldenberg RL, Moawad AH, Meis PJ, Iams JD, Das AF, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999;181:1216-21.
14. Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005;105:267-72.
15. Cost analysis. In: Drummond MF, Sculpher MJ, Torrance GW, O’Brien, Stoddart GL, editors. Methods for the economic evaluation of health care programmes. New York (NY): Oxford University Press; 2005. p. 77.
16. Nicholson WK, Frick KD, Powe NR. Economic burden of hospitalizations for preterm labor in the United States. Obstet Gynecol 2000;96:95-101.
17. Teng TO, Wallace A. One thousand health-related quality-of-life outcomes. Med Care 2000;38:583-637.
18. Medicare. US Department of Health and Human Services, National Limitations—Clinical Lab, Washington, DC (1995).
19. Kinosian BP, Eisenberg JM. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. JAMA 1988;259:2249-54.
20. Wagner JL, Herdman RC, Wadhwa S. Cost-effectiveness of colorectal cancer screening in the elderly. Ann Intern Med 1991;115:807-17.
21. Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol 2005;193:1127-31.
22. Meis PJ, Dombrowski MP, Leindecker S, Moawad AH, Northern A, Iams JD, et al. Does progesterone treatment influence risk factors for recurrent preterm delivery? Obstet Gynecol 2005;106:557-61.
23. Petrou S. The economic consequences of preterm birth during the first 10 years of life. BJOG 2005;112:10-5.
24. McCormick MC, Bernbaum JC, Eisenberg JM, Kustra SL, Finnegan E. Costs incurred by parents of very low birth weight infants after the initial neonatal hospitalization. Pediatrics 1991;88:533-41.
25. Rogowski J. Cost-effectiveness of care for very low birth weight infants. Pediatrics 1998;102:35-43.